Atara Biotherapeutics Stock Price, News & Analysis (NASDAQ:ATRA)

$14.50 -0.30 (-2.03 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$14.80
Today's Range$14.35 - $15.00
52-Week Range$11.80 - $23.00
Volume346,300 shs
Average Volume229,167 shs
Market Capitalization$452.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Debt-to-Equity RatioN/A
Current Ratio12.49%
Quick Ratio12.49%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$8.79 per share
Price / Book1.65

Profitability

Trailing EPS($3.47)
Net Income$-79,040,000.00
Net MarginsN/A
Return on Equity-44.82%
Return on Assets-41.82%

Miscellaneous

Employees96
Outstanding Shares30,600,000

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.97) by $0.05. View Atara Biotherapeutics' Earnings History.

Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?

5 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their forecasts range from $10.00 to $47.00. On average, they anticipate Atara Biotherapeutics' share price to reach $26.75 in the next year. View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

  • 1. Canaccord Genuity analysts commented, "Both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint. Sage plans to submit an NDA in 1H18. Brexanolone has both Breakthrough status and PRIME designation and we expect FDA approval/launch in 2H18. We have modest expectations for overall commercial opportunity w/ brexanolone as a 60-hr IV infusion, but we highlight that it will address an unmet need as the first drug approved for PPD. We ultimately expect oral ‘217 to replace brexanolone for this indication and view outcome as a positive for ‘217 program as mechanism is now validated. We still see significant upside opportunity for Sage shares w/ Phase 2 ‘217 MDD data reporting out by YE. Positive results would signify potential for broad utility across mood disorders." (11/9/2017)
  • 2. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (8/28/2017)

Who are some of Atara Biotherapeutics' key competitors?

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:

  • Isaac E. Ciechanover M.D., Chairman of the Board, President, Chief Executive Officer (Age 46)
  • John F. McGrath Jr., Chief Financial Officer, Executive Vice President (Age 52)
  • Joseph Newell, Executive Vice President, Chief Technical Operations Officer (Age 47)
  • Christopher M. Haqq M.D. Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 50)
  • Heather D. Turner, Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy (Age 43)
  • Mitchall G. Clark, Executive Vice President and Chief Regulatory and Quality Assurance Officer (Age 55)
  • Gad Soffer, Executive Vice President and Chief Strategy Officer (Age 39)
  • Kanya Rajangam M.D. Ph.D., Senior Vice President, Chief Medical Officer
  • Carol G. Gallagher Pharm.D., Lead Independent Director (Age 52)
  • Eric L. Dobmeier, Independent Director (Age 48)

Who owns Atara Biotherapeutics stock?

Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Neuberger Berman Group LLC (3.64%), RTW Investments LP (2.14%), Artal Group S.A. (1.96%), Schwab Charles Investment Management Inc. (0.28%), IndexIQ Advisors LLC (0.14%) and California State Teachers Retirement System (0.13%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Eric Dobmeier, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.

Who sold Atara Biotherapeutics stock? Who is selling Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Schwab Charles Investment Management Inc. and California State Teachers Retirement System. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.

Who bought Atara Biotherapeutics stock? Who is buying Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Artal Group S.A., Perceptive Advisors LLC, Essex Investment Management Co. LLC, IndexIQ Advisors LLC, Russell Investments Group Ltd., SG Americas Securities LLC and Alps Advisors Inc.. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy Atara Biotherapeutics stock?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.50.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $452.82 million. The biotechnology company earns $-79,040,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis. Atara Biotherapeutics employs 96 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


MarketBeat Community Rating for Atara Biotherapeutics (ATRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  187 (Thanks for Voting!)
Underperform Votes:  116 (Thanks for Voting!)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Atara Biotherapeutics (NASDAQ:ATRA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.332.43
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.75$26.75$25.75$27.33
Price Target Upside: 100.37% upside100.37% upside76.37% upside44.62% upside

Atara Biotherapeutics (NASDAQ:ATRA) Consensus Price Target History

Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$20.00N/AView Rating Details
10/5/2017Jefferies GroupReiterated RatingBuy$30.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/16/2017CitigroupSet Price TargetSell$10.00HighView Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$40.00 -> $34.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Atara Biotherapeutics (NASDAQ:ATRA) Earnings History and Estimates Chart

Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.97)($1.02)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.89)($0.94)ViewN/AView Earnings Details
3/9/201712/31/2016($0.98)($0.63)ViewN/AView Earnings Details
11/4/2016Q3 2016($0.79)($0.88)ViewN/AView Earnings Details
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
3/3/2016Q4 2015($0.48)($0.75)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.42)($0.43)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Atara Biotherapeutics (NASDAQ:ATRA) Earnings Estimates

2017 EPS Consensus Estimate: ($3.86)
2018 EPS Consensus Estimate: ($3.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.78)($0.75)($0.77)
Q2 20172($0.92)($0.91)($0.92)
Q3 20172($1.10)($0.95)($1.03)
Q4 20172($1.32)($0.98)($1.15)
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($1.00)($1.00)($1.00)
Q3 20181($1.02)($1.02)($1.02)
Q4 20181($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.20%
Institutional Ownership Percentage: 85.61%
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017Isaac E CiechanoverCEOSell4,400$14.25$62,700.00View SEC Filing  
11/17/2017Gad SofferEVPSell7,000$15.00$105,000.00View SEC Filing  
11/16/2017Carol Giltner GallagherDirectorSell1,184$14.20$16,812.80View SEC Filing  
11/15/2017Christopher HaqqEVPSell1,604$13.36$21,429.44View SEC Filing  
11/14/2017Isaac E CiechanoverCEOSell4,400$13.47$59,268.00View SEC Filing  
10/27/2017Isaac E CiechanoverCEOSell4,400$13.59$59,796.00View SEC Filing  
10/16/2017Christopher HaqqEVPSell6,000$14.35$86,100.00View SEC Filing  
10/12/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
10/11/2017Isaac E CiechanoverCEOSell2,200$15.25$33,550.00View SEC Filing  
9/20/2017Isaac E CiechanoverCEOSell4,400$15.54$68,376.00View SEC Filing  
9/15/2017Christopher HaqqEVPSell6,000$15.30$91,800.00View SEC Filing  
9/7/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
8/23/2017Isaac E CiechanoverCEOSell4,400$13.54$59,576.00View SEC Filing  
8/16/2017Carol Giltner GallagherDirectorSell1,184$14.30$16,931.20View SEC Filing  
8/16/2017John McgrathCFOSell4,200$14.31$60,102.00View SEC Filing  
8/16/2017Mitchall G. ClarkEVPSell3,021$14.33$43,290.93View SEC Filing  
8/15/2017Christopher HaqqEVPSell7,604$14.75$112,159.00View SEC Filing  
8/11/2017Isaac E CiechanoverCEOSell4,400$14.67$64,548.00View SEC Filing  
7/25/2017Isaac E CiechanoverCEOSell5,500$16.49$90,695.00View SEC Filing  
7/24/2017Isaac E CiechanoverCEOSell2,800$16.94$47,432.00View SEC Filing  
7/17/2017Christopher HaqqEVPSell6,000$14.92$89,520.00View SEC Filing  
6/15/2017Christopher HaqqEVPSell6,000$12.65$75,900.00View SEC Filing  
6/9/2017Carol Giltner GallagherDirectorSell1,000$13.15$13,150.00View SEC Filing  
5/31/2017Isaac E CiechanoverCEOSell6,900$13.35$92,115.00View SEC Filing  
5/30/2017Isaac E CiechanoverCEOSell3,450$13.44$46,368.00View SEC Filing  
5/18/2017Isaac E CiechanoverCEOSell4,800$14.91$71,568.00View SEC Filing  
5/16/2017Carol Giltner GallagherDirectorSell1,184$15.25$18,056.00View SEC Filing  
5/16/2017Gad SofferEVPSell12,674$15.16$192,137.84View SEC Filing  
5/16/2017John McgrathCFOSell4,000$15.11$60,440.00View SEC Filing  
4/26/2017Isaac E CiechanoverCEOSell7,200$17.56$126,432.00View SEC Filing  
4/25/2017Isaac E CiechanoverCEOSell3,600$17.33$62,388.00View SEC Filing  
4/17/2017Christopher HaqqEVPSell6,000$17.28$103,680.00View SEC Filing  
4/11/2017Isaac E CiechanoverCEOSell7,200$17.03$122,616.00View SEC Filing  
3/28/2017Isaac E CiechanoverCEOSell16,000$20.06$320,960.00View SEC Filing  
3/23/2017John McgrathCFOSell14,000$20.65$289,100.00View SEC Filing  
3/17/2017Isaac E CiechanoverCEOSell30,800$19.38$596,904.00View SEC Filing  
3/10/2017Gad SofferEVPSell2,500$20.00$50,000.00View SEC Filing  
3/10/2017John McgrathCFOSell24,000$20.00$480,000.00View SEC Filing  
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.40View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.35View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.00View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.00View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Atara Biotherapeutics (NASDAQ ATRA) News Headlines

Source:
DateHeadline
Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)
finance.yahoo.com - December 11 at 12:06 PM
Atara Biotherapeutics, Inc. (ATRA) to Post FY2019 Earnings of ($5.23) Per Share, Jefferies Group ForecastsAtara Biotherapeutics, Inc. (ATRA) to Post FY2019 Earnings of ($5.23) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - December 8 at 6:36 PM
Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 SharesAtara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares
www.americanbankingnews.com - December 1 at 10:50 PM
Analyzing Atara Biotherapeutics (ATRA) and Its PeersAnalyzing Atara Biotherapeutics (ATRA) and Its Peers
www.americanbankingnews.com - November 24 at 9:12 PM
Atara Biotherapeutics, Inc. (ATRA) Given Average Rating of "Hold" by AnalystsAtara Biotherapeutics, Inc. (ATRA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 23 at 5:46 PM
Atara Biotherapeutics, Inc. (ATRA) Expected to Announce Earnings of -$1.15 Per ShareAtara Biotherapeutics, Inc. (ATRA) Expected to Announce Earnings of -$1.15 Per Share
www.americanbankingnews.com - November 20 at 5:22 PM
Christopher Haqq Sells 1,604 Shares of Atara Biotherapeutics, Inc. (ATRA) StockChristopher Haqq Sells 1,604 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
www.americanbankingnews.com - November 17 at 9:50 PM
Atara Biotherapeutics, Inc. (ATRA) Director Carol Giltner Gallagher Sells 1,184 SharesAtara Biotherapeutics, Inc. (ATRA) Director Carol Giltner Gallagher Sells 1,184 Shares
www.americanbankingnews.com - November 17 at 9:50 PM
Gad Soffer Sells 7,000 Shares of Atara Biotherapeutics, Inc. (ATRA) StockGad Soffer Sells 7,000 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
www.americanbankingnews.com - November 17 at 8:58 PM
Analyzing Atara Biotherapeutics (ATRA) and Aduro Biotech (ADRO)Analyzing Atara Biotherapeutics (ATRA) and Aduro Biotech (ADRO)
www.americanbankingnews.com - November 16 at 1:06 AM
Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of StockInsider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells 4,400 Shares of Stock
www.americanbankingnews.com - November 14 at 11:26 PM
Atara Biotherapeutics, Inc. (ATRA) Posts  Earnings Results, Misses Expectations By $0.05 EPSAtara Biotherapeutics, Inc. (ATRA) Posts Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent HighlightsAtara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - November 9 at 5:22 PM
Atara Biotherapeutics reports 3Q lossAtara Biotherapeutics reports 3Q loss
finance.yahoo.com - November 9 at 5:22 PM
Atara Biotherapeutics (ATRA) Buy Rating Reiterated at Canaccord GenuityAtara Biotherapeutics' (ATRA) Buy Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - November 9 at 3:42 PM
Atara Biotherapeutics to Participate in Four Upcoming Investor ConferencesAtara Biotherapeutics to Participate in Four Upcoming Investor Conferences
finance.yahoo.com - November 7 at 5:58 PM
What Is Atara Biotherapeutics Inc’s (ATRA) Share Price Doing?What Is Atara Biotherapeutics Inc’s (ATRA) Share Price Doing?
finance.yahoo.com - November 2 at 4:42 PM
ATARA Biotherapeutics (ATRA) Announces Two Presentations at ASHATARA Biotherapeutics (ATRA) Announces Two Presentations at ASH
www.streetinsider.com - November 1 at 4:48 PM
ATARA Biotherapeutics (ATRA) Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of CMVATARA Biotherapeutics (ATRA) Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of CMV
www.streetinsider.com - October 27 at 5:24 AM
Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) InfectionAtara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection
finance.yahoo.com - October 26 at 10:03 AM
Atara Biotherapeutics Inc (ATRA) to Release Earnings on ThursdayAtara Biotherapeutics Inc (ATRA) to Release Earnings on Thursday
www.americanbankingnews.com - October 26 at 3:26 AM
Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190
finance.yahoo.com - October 25 at 5:20 PM
Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
finance.yahoo.com - October 19 at 4:42 PM
Christopher Haqq Sells 6,000 Shares of Atara Biotherapeutics, Inc. (ATRA) StockChristopher Haqq Sells 6,000 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
www.americanbankingnews.com - October 17 at 7:48 PM
Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)
finance.yahoo.com - October 16 at 4:59 PM
Isaac E. Ciechanover Sells 2,200 Shares of Atara Biotherapeutics, Inc. (ATRA) StockIsaac E. Ciechanover Sells 2,200 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
www.americanbankingnews.com - October 13 at 8:32 PM
Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA ApprovalYour Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval
seekingalpha.com - October 13 at 4:46 PM
Goldman Sachs Group, Inc. (The) Reiterates "Neutral" Rating for Atara Biotherapeutics, Inc. (ATRA)Goldman Sachs Group, Inc. (The) Reiterates "Neutral" Rating for Atara Biotherapeutics, Inc. (ATRA)
www.americanbankingnews.com - October 6 at 9:08 PM
Jefferies Group LLC Reaffirms "Buy" Rating for Atara Biotherapeutics, Inc. (ATRA)Jefferies Group LLC Reaffirms "Buy" Rating for Atara Biotherapeutics, Inc. (ATRA)
www.americanbankingnews.com - October 5 at 1:32 PM
Atara Biotherapeutics, Inc. (ATRA) Receives Consensus Rating of "Hold" from AnalystsAtara Biotherapeutics, Inc. (ATRA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 4 at 2:54 PM
Retrophin (RTRX) & Atara Biotherapeutics (ATRA) Critical SurveyRetrophin (RTRX) & Atara Biotherapeutics (ATRA) Critical Survey
www.americanbankingnews.com - September 19 at 2:30 PM
Atara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 6,000 SharesAtara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 6,000 Shares
www.americanbankingnews.com - September 18 at 8:08 PM
Atara Biotherapeutics, Inc. (ATRA) Earns Buy Rating from Canaccord GenuityAtara Biotherapeutics, Inc. (ATRA) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 17 at 10:22 PM
Should You Buy Atara Biotherapeutics Inc (ATRA) Now?Should You Buy Atara Biotherapeutics Inc (ATRA) Now?
finance.yahoo.com - September 16 at 8:58 PM
ATARA Biotherapeutics (ATRA) Announces Positive Health Canada Regulatory Feedback for ATA129ATARA Biotherapeutics (ATRA) Announces Positive Health Canada Regulatory Feedback for ATA129
www.streetinsider.com - September 11 at 4:14 PM
Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129
finance.yahoo.com - September 11 at 4:14 PM
Atara Biotherapeutics, Inc. (ATRA) Given Average Rating of "Hold" by BrokeragesAtara Biotherapeutics, Inc. (ATRA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 9 at 11:04 AM
Atara Biotherapeutics, Inc. (ATRA) CEO Sells $66,088.00 in StockAtara Biotherapeutics, Inc. (ATRA) CEO Sells $66,088.00 in Stock
www.americanbankingnews.com - September 8 at 8:40 PM
ATARA Biotherapeutics (ATRA) Announces FDA Orphan Drug Designation for ATA230ATARA Biotherapeutics (ATRA) Announces FDA Orphan Drug Designation for ATA230
www.streetinsider.com - September 5 at 10:51 PM
Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230
finance.yahoo.com - September 5 at 5:48 PM
-$1.03 EPS Expected for Atara Biotherapeutics, Inc. (ATRA) This Quarter-$1.03 EPS Expected for Atara Biotherapeutics, Inc. (ATRA) This Quarter
www.americanbankingnews.com - September 4 at 8:18 PM
Atara Biotherapeutics, Inc. (ATRA) Given Buy Rating at Jefferies Group LLCAtara Biotherapeutics, Inc. (ATRA) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - August 31 at 6:20 PM
Featured Company News – Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South KoreaFeatured Company News – Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea
finance.yahoo.com - August 25 at 5:49 PM
Atara Biotherapeutics, Inc. (ATRA) CEO Sells $59,576.00 in StockAtara Biotherapeutics, Inc. (ATRA) CEO Sells $59,576.00 in Stock
www.americanbankingnews.com - August 24 at 7:57 PM
ATARA Biotherapeutics (ATRA) Names Dr. Kanya Rajangam as SVP and CMOATARA Biotherapeutics (ATRA) Names Dr. Kanya Rajangam as SVP and CMO
www.streetinsider.com - August 23 at 6:39 AM
John Mcgrath Sells 4,200 Shares of Atara Biotherapeutics, Inc. (ATRA) StockJohn Mcgrath Sells 4,200 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
www.americanbankingnews.com - August 17 at 8:50 PM
Insider Selling: Atara Biotherapeutics, Inc. (ATRA) EVP Sells 3,021 Shares of StockInsider Selling: Atara Biotherapeutics, Inc. (ATRA) EVP Sells 3,021 Shares of Stock
www.americanbankingnews.com - August 17 at 8:50 PM
Atara Biotherapeutics, Inc. (ATRA) EVP Sells $112,159.00 in StockAtara Biotherapeutics, Inc. (ATRA) EVP Sells $112,159.00 in Stock
www.americanbankingnews.com - August 17 at 8:32 PM
Why this Bay Area biotech giant chose SoCal for its new manufacturing plantWhy this Bay Area biotech giant chose SoCal for its new manufacturing plant
www.bizjournals.com - August 16 at 9:49 PM
Atara Biotherapeutics, Inc. (ATRA) Receives Average Rating of "Hold" from BrokeragesAtara Biotherapeutics, Inc. (ATRA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 15 at 2:50 PM

SEC Filings

Atara Biotherapeutics (NASDAQ:ATRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Atara Biotherapeutics (NASDAQ:ATRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Atara Biotherapeutics (NASDAQ ATRA) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.